Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.99
NAS:INCY's Cash to Debt is ranked lower than
81% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:INCY: 0.99 )
Ranked among companies with meaningful Cash to Debt only.
NAS:INCY' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.2 Max: No Debt
Current: 0.99
Equity to Asset 0.21
NAS:INCY's Equity to Asset is ranked lower than
87% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:INCY: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
NAS:INCY' s Equity to Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.07 Max: 0.79
Current: 0.21
-1.83
0.79
Interest Coverage 3.53
NAS:INCY's Interest Coverage is ranked lower than
92% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:INCY: 3.53 )
Ranked among companies with meaningful Interest Coverage only.
NAS:INCY' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 0.32 Max: 3.53
Current: 3.53
0.02
3.53
F-Score: 7
Z-Score: 8.69
M-Score: -1.27
WACC vs ROIC
10.41%
120.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.47
NAS:INCY's Operating margin (%) is ranked higher than
84% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:INCY: 15.47 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:INCY' s Operating margin (%) Range Over the Past 10 Years
Min: -4064.53  Med: -78.07 Max: 15.47
Current: 15.47
-4064.53
15.47
Net-margin (%) 7.87
NAS:INCY's Net-margin (%) is ranked higher than
79% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:INCY: 7.87 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:INCY' s Net-margin (%) Range Over the Past 10 Years
Min: -4565.45  Med: -110.46 Max: 7.87
Current: 7.87
-4565.45
7.87
ROE (%) 44.09
NAS:INCY's ROE (%) is ranked higher than
97% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:INCY: 44.09 )
Ranked among companies with meaningful ROE (%) only.
NAS:INCY' s ROE (%) Range Over the Past 10 Years
Min: 14.59  Med: 14.59 Max: 44.09
Current: 44.09
14.59
44.09
ROA (%) 6.87
NAS:INCY's ROA (%) is ranked higher than
87% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:INCY: 6.87 )
Ranked among companies with meaningful ROA (%) only.
NAS:INCY' s ROA (%) Range Over the Past 10 Years
Min: -70.43  Med: -18.85 Max: 6.87
Current: 6.87
-70.43
6.87
ROC (Joel Greenblatt) (%) 121.38
NAS:INCY's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:INCY: 121.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:INCY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4727.38  Med: -376.81 Max: 121.38
Current: 121.38
-4727.38
121.38
Revenue Growth (3Y)(%) 20.70
NAS:INCY's Revenue Growth (3Y)(%) is ranked higher than
73% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:INCY: 20.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:INCY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.4  Med: 19.6 Max: 194.1
Current: 20.7
-61.4
194.1
EBITDA Growth (3Y)(%) 28.60
NAS:INCY's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:INCY: 28.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:INCY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.2  Med: -8.5 Max: 219.3
Current: 28.6
-33.2
219.3
» NAS:INCY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

INCY Guru Trades in Q3 2015

Paul Tudor Jones 9,555 sh (New)
John Burbank 309,627 sh (New)
Ken Fisher 14,495 sh (+5.84%)
Vanguard Health Care Fund 9,233,028 sh (-1.90%)
Joel Greenblatt 4,861 sh (-53.09%)
Jim Simons 33,200 sh (-87.93%)
» More
Q4 2015

INCY Guru Trades in Q4 2015

Frank Sands 4,420,966 sh (New)
George Soros 4,200 sh (New)
Vanguard Health Care Fund 9,615,828 sh (+4.15%)
Ken Fisher 14,818 sh (+2.23%)
Samuel Isaly 431,500 sh (unchged)
John Burbank Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 8,513 sh (-10.91%)
» More
Q1 2016

INCY Guru Trades in Q1 2016

Joel Greenblatt 52,500 sh (New)
Jim Simons 304,000 sh (New)
Paul Tudor Jones 77,400 sh (+809.20%)
Vanguard Health Care Fund 16,227,748 sh (+68.76%)
Ken Fisher 14,839 sh (+0.14%)
George Soros Sold Out
Frank Sands 3,819,401 sh (-13.61%)
Samuel Isaly 429,400 sh (-0.49%)
» More
Q2 2016

INCY Guru Trades in Q2 2016

George Soros 7,500 sh (New)
Joel Greenblatt 142,607 sh (+171.63%)
Frank Sands 4,467,286 sh (+16.96%)
Paul Tudor Jones 81,409 sh (+5.18%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Ken Fisher 14,818 sh (-0.14%)
Jim Simons 164,567 sh (-45.87%)
Samuel Isaly 363,900 sh (-15.25%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:BMRN, OTCPK:ALIOY, OTCPK:UCBJF, NAS:MDVN, NAS:VRTX, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, OTCPK:NVZMY, NAS:ALNY, NAS:TSRO, NAS:UTHR, NAS:GRFS, NAS:ALXN, NAS:IONS, NAS:ICPT, NAS:TECH, NAS:ACAD, NAS:EXEL » details
Traded in other countries:ICY.Germany,
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.

Ratios

vs
industry
vs
history
P/E(ttm) 240.06
INCY's P/E(ttm) is ranked lower than
94% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. INCY: 240.06 )
Ranked among companies with meaningful P/E(ttm) only.
INCY' s P/E(ttm) Range Over the Past 10 Years
Min: 200.29  Med: 310.86 Max: 5661.5
Current: 240.06
200.29
5661.5
Forward P/E 68.97
INCY's Forward P/E is ranked lower than
92% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. INCY: 68.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 240.06
INCY's PE(NRI) is ranked lower than
94% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INCY: 240.06 )
Ranked among companies with meaningful PE(NRI) only.
INCY' s PE(NRI) Range Over the Past 10 Years
Min: 200.29  Med: 310.86 Max: 5661.5
Current: 240.06
200.29
5661.5
Price/Owner Earnings (ttm) 329.43
INCY's Price/Owner Earnings (ttm) is ranked lower than
92% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. INCY: 329.43 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
INCY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.73  Med: 138.24 Max: 3235.14
Current: 329.43
10.73
3235.14
P/B 57.68
INCY's P/B is ranked lower than
98% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. INCY: 57.68 )
Ranked among companies with meaningful P/B only.
INCY' s P/B Range Over the Past 10 Years
Min: 48.14  Med: 118.27 Max: 391.93
Current: 57.68
48.14
391.93
P/S 18.31
INCY's P/S is ranked lower than
60% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. INCY: 18.31 )
Ranked among companies with meaningful P/S only.
INCY' s P/S Range Over the Past 10 Years
Min: 7.13  Med: 22.17 Max: 239.71
Current: 18.31
7.13
239.71
PFCF 203.63
INCY's PFCF is ranked lower than
93% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. INCY: 203.63 )
Ranked among companies with meaningful PFCF only.
INCY' s PFCF Range Over the Past 10 Years
Min: 6.56  Med: 180.91 Max: 1176.61
Current: 203.63
6.56
1176.61
POCF 90.01
INCY's POCF is ranked lower than
88% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. INCY: 90.01 )
Ranked among companies with meaningful POCF only.
INCY' s POCF Range Over the Past 10 Years
Min: 6.52  Med: 144.84 Max: 775.18
Current: 90.01
6.52
775.18
EV-to-EBIT 146.67
INCY's EV-to-EBIT is ranked lower than
92% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. INCY: 146.67 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8436.1  Med: -8.4 Max: 1546.6
Current: 146.67
-8436.1
1546.6
EV-to-EBITDA 105.44
INCY's EV-to-EBITDA is ranked lower than
90% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. INCY: 105.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -662.5  Med: -6.5 Max: 2618.5
Current: 105.44
-662.5
2618.5
Current Ratio 3.98
INCY's Current Ratio is ranked lower than
53% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. INCY: 3.98 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.67 Max: 21.14
Current: 3.98
1.51
21.14
Quick Ratio 3.95
INCY's Quick Ratio is ranked lower than
51% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. INCY: 3.95 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.66 Max: 21.14
Current: 3.95
1.51
21.14
Days Inventory 27.37
INCY's Days Inventory is ranked higher than
84% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. INCY: 27.37 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 122.28 Max: 323.15
Current: 27.37
14.49
323.15
Days Sales Outstanding 50.21
INCY's Days Sales Outstanding is ranked higher than
61% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. INCY: 50.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 38.86 Max: 6447.52
Current: 50.21
12.25
6447.52
Days Payable 411.57
INCY's Days Payable is ranked higher than
91% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. INCY: 411.57 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 407.13  Med: 7019.64 Max: 32457.1
Current: 411.57
407.13
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.80
INCY's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. INCY: -11.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.4  Med: -7.6 Max: -0.6
Current: -11.8
-13.4
-0.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.84
INCY's Price/Median PS Value is ranked higher than
66% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. INCY: 0.84 )
Ranked among companies with meaningful Price/Median PS Value only.
INCY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 0.71 Max: 8.65
Current: 0.84
0.1
8.65
Earnings Yield (Greenblatt) (%) 0.72
INCY's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. INCY: 0.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INCY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.6 Max: 1.2
Current: 0.72
0.1
1.2

More Statistics

Revenue (TTM) (Mil) $941.2
EPS (TTM) $ 0.38
Beta1.19
Short Percentage of Float4.83%
52-Week Range $55.00 - 131.33
Shares Outstanding (Mil)188.00

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,035 1,464 1,750 2,097
EPS ($) 0.15 1.37 2.15 2.91
EPS w/o NRI ($) 0.15 1.37 2.15 2.91
EPS Growth Rate
(3Y to 5Y Estimate)
170.10%
Dividends Per Share ($)
» More Articles for NAS:INCY

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
Top Insider Trades of the Past Week Feb 19 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 

More From Other Websites
Biotech stocks have plenty of catalysts around the corner Sep 30 2016
Street Talk: INCY, EBAY & more Sep 29 2016
Incyte upgraded by Raymond James Sep 29 2016
Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda®... Sep 28 2016
6:13 am Incyte announces that the ESMO has published an abstract containing updated data from the... Sep 28 2016
Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda®... Sep 28 2016
NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis Sep 27 2016
Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98 Sep 26 2016
Incyte Corp. – Value Analysis (NASDAQ:INCY) : September 21, 2016 Sep 21 2016
Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 20, 2016 Sep 20 2016
After Losing Medivation, Who Is Gilead Going After Next? Sep 19 2016
ETF’s with exposure to Incyte Corp. : September 9, 2016 Sep 09 2016
Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood... Sep 08 2016
Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 7, 2016 Sep 07 2016
These Collaborations Could Boost Jakafi Sales Sep 06 2016
Incyte’s Profitability Improves, Allowing for Revised Guidance Sep 05 2016
How Is Incyte’s Only FDA-Approved Drug Performing? Sep 05 2016
Incyte’s Product Portfolio Includes Potentially Lucrative Drugs Sep 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)